Rationalizing a prospective coupling effect of cannabinoids with the current pharmacotherapy for melanoma treatment

WIREs Mech Dis. 2024 Jan-Feb;16(1):e1633. doi: 10.1002/wsbm.1633. Epub 2023 Nov 3.

Abstract

Melanoma is one of the leading fatal forms of cancer, yet from a treatment perspective, we have minimal control over its reoccurrence and resistance to current pharmacotherapies. The endocannabinoid system (ECS) has recently been accepted as a multifaceted homeostatic regulator, influencing various physiological processes across different biological compartments, including the skin. This review presents an overview of the pathophysiology of melanoma, current pharmacotherapy used for treatment, and the challenges associated with the different pharmacological approaches. Furthermore, it highlights the utility of cannabinoids as an additive remedy for melanoma by restoring the balance between downregulated immunomodulatory pathways and elevated inflammatory cytokines during chronic skin conditions as one of the suggested critical approaches in treating this immunogenic tumor. This article is categorized under: Cancer > Molecular and Cellular Physiology.

Keywords: cancer treatment; cannabinoids; mechanisms; melanoma; pharmacotherapy.

Publication types

  • Review

MeSH terms

  • Cannabinoids* / pharmacology
  • Endocannabinoids / therapeutic use
  • Humans
  • Melanoma* / drug therapy
  • Prospective Studies
  • Skin / metabolism

Substances

  • Cannabinoids
  • Endocannabinoids